Medtronic plc has announced the appointment of Chad Spooner as the Chief Financial Officer (CFO) of MiniMed. This move comes ahead of Medtronic’s plan to separate MiniMed into a standalone, publicly traded company. Spooner will take on his new role effective July 14, 2025, where he will oversee the Finance function for Medtronic Diabetes and support growth initiatives as MiniMed prepares for independence.
Spooner brings over 25 years of financial leadership experience across various sectors, including healthcare. His previous role was CFO at BIC, where he contributed significantly to the company’s transformation efforts. Spooner’s career also includes positions at General Electric and other firms like Raffaela Apparel Group and Slingshot Health.
Que Dallara, Executive Vice President and President of Medtronic Diabetes and CEO Designate of MiniMed, expressed enthusiasm about Spooner’s appointment: “We’re excited to welcome Chad to the executive team at such a pivotal time for our business.”
In June, Medtronic announced that following its separation from Medtronic, the company would be named MiniMed. The name reflects its long-standing contribution to diabetes care over four decades.
Spooner shared his excitement about joining MiniMed: “I’m excited for the opportunity to help shape the future of a company with such a meaningful Mission.”
The separation is expected within 18 months through capital market transactions subject to customary conditions and legal requirements.
The press release contains forward-looking statements subject to risks and uncertainties related to Medtronic’s ability to successfully complete the separation process and other factors affecting business operations.
###
